Chen, W., Niu, J., Wu, S., Xu, H., Cao, L., Li, M., Luo, H., Ke, L., Yan, Y., Wang, G., He, Y. (2026). Phase II study of bevacizumab plus trifluridine/tipiracil and irinotecan as second-line therapy for RAS wild-type metastatic colorectal cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e15578